Prospective Study on Safety and Efficacy of Stenting for Chronic Middle Cerebral Artery Occlusion With Limb Dysfunction
Launched by HUIZHOU MUNICIPAL CENTRAL HOSPITAL · May 15, 2024
Trial Information
Current as of March 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age and gender: individuals aged 18 and above, regardless of gender.
- • Diagnosis: chronic MCA occlusion confirmed by imaging studies (such as Magnetic Resonance Imaging (MRI) or Computed Tomography (CT)) for more than 3 months.
- • Symptoms: neurological deficits caused by MCA occlusion, such as hemiplegia, speech disorders, etc.
- • Treatment History: no stenting revascularization for MCA occlusion within the past three months.
- Exclusion Criteria:
- • Acute stroke: occurrence of an acute cerebrovascular event within the past three months.
- • Other significant diseases: such as severe heart disease, liver or kidney dysfunction, cerebral hemorrhage, active bleeding, or coagulation disorders.
- • Allergy to contrast agents.
- • Severe mental illness or inability to comply with study requirements.
- • Pregnant or breastfeeding women.
- • Discovery of MCA occlusion without any symptoms.
- • Participation in other clinical trials within the past six months.
About Huizhou Municipal Central Hospital
Huizhou Municipal Central Hospital is a leading healthcare institution located in Huizhou, China, dedicated to advancing medical research and patient care. As a clinical trial sponsor, the hospital leverages its state-of-the-art facilities and a multidisciplinary team of experienced professionals to conduct innovative research aimed at improving therapeutic outcomes. Committed to ethical standards and regulatory compliance, Huizhou Municipal Central Hospital collaborates with various stakeholders to facilitate the development of new treatments, contributing to the global body of medical knowledge and enhancing the health of the community it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Huizhou, Guangdong, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
